Danaher to acquire mass spectrometry business from Life Technologies Corporation

Life Technologies Corporation (NASDAQ:LIFE) today announced it has signed a definitive agreement to sell its ownership stake in its mass spectrometry business, operated as a joint venture, to Danaher Corporation (NYSE:DHR) for $450 million in cash. Danaher has also signed an agreement to acquire Life Technologies’ joint venture partner in the mass spectrometry business, MDS Analytical Technologies, a division of MDS Inc. (NYSE:MDZ). The transaction is expected to close in the fourth quarter of 2009.

“The sale of our mass spectrometry business will enable us to continue our focus on our core competencies,” said Greg Lucier, Chairman and Chief Executive Officer of Life Technologies. “By concentrating on biological solutions that leverage our expertise in DNA, RNA, proteins and cells, we will continue to drive breakthroughs in life science research, genomic medicine, molecular diagnostics and applied markets.”

Mr. Lucier continued, “Our mass spectrometry joint venture with MDS is a market leader and we are pleased that a strong company like Danaher will integrate the two sides of this excellent franchise into one organization. Customers, employees and business partners will all benefit from now having one company represent this award-winning, revitalized product line in the future.”

Life Technologies does not expect the sale of its mass spectrometry business to affect its previously announced full year 2009 earnings expectations. In addition, the company reiterated its synergy targets for the Invitrogen and Applied Biosystems merger of $95 million in 2009 and $175 million by 2011.

“We are confident the transition of the mass spectrometry business to Danaher will go smoothly, as we plan to use the same rigor and process in this divestiture that we’ve been using for the Invitrogen and Applied Biosystems merger,” said Mark Stevenson, President and Chief Operating Officer of Life Technologies. “The same team that has handled the merger integration process will handle this divestiture.”

The transaction is subject to customary closing conditions, and is also conditioned upon the completion of MDS Inc.’s sale of its Analytical Technologies division, which itself is conditioned upon approval from MDS’ shareholders. The transaction is expected to close in the fourth quarter of 2009 and is not subject to any financing conditions. Moelis & Company and Thomas Weisel Partners are acting as financial advisors and DLA Piper is serving as legal counsel to Life Technologies.

www.lifetechnologies.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Danaher. (2009, September 02). Danaher to acquire mass spectrometry business from Life Technologies Corporation. News-Medical. Retrieved on April 23, 2024 from https://www.news-medical.net/news/20090902/Danaher-to-acquire-mass-spectrometry-business-from-Life-Technologies-Corporation.aspx.

  • MLA

    Danaher. "Danaher to acquire mass spectrometry business from Life Technologies Corporation". News-Medical. 23 April 2024. <https://www.news-medical.net/news/20090902/Danaher-to-acquire-mass-spectrometry-business-from-Life-Technologies-Corporation.aspx>.

  • Chicago

    Danaher. "Danaher to acquire mass spectrometry business from Life Technologies Corporation". News-Medical. https://www.news-medical.net/news/20090902/Danaher-to-acquire-mass-spectrometry-business-from-Life-Technologies-Corporation.aspx. (accessed April 23, 2024).

  • Harvard

    Danaher. 2009. Danaher to acquire mass spectrometry business from Life Technologies Corporation. News-Medical, viewed 23 April 2024, https://www.news-medical.net/news/20090902/Danaher-to-acquire-mass-spectrometry-business-from-Life-Technologies-Corporation.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Danaher reports 4% increase in Q2 revenues